Immunome (NASDAQ:IMNM) Stock Rating Lowered by Wall Street Zen

Immunome (NASDAQ:IMNM) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Sunday, Wall Street Zen reports.

Several other analysts have also recently issued reports on IMNM. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Immunome in a research report on Thursday, September 10th. Stifel Nicolaus assumed coverage on Immunome in a research note on Wednesday, September 30th. They set a “hold” rating and a $24.00 price objective on the stock. Alliance Global Partners assumed coverage on Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 price objective on the stock. Truist Financial upped their price objective on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Wedbush raised their price objective on Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Immunome Stock Performance

IMNM stock opened at $21.17 on Friday. The firm has a fifty day moving average price of $25.32 and a 200 day moving average price of $22.88. Immunome has a fifty-two week low of $12.41 and a fifty-two week high of $30.06. The firm has a market cap of $2.40 billion, a PE ratio of -8.37 and a beta of 2.55.

Immunome (NASDAQ:IMNM) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, equities analysts predict that Immunome will post -2.43 EPS for the current year.

Insider Activity at Immunome

In related news, insider Kinney Horn sold 90,616 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the sale, the insider directly owned 50,366 shares of the company’s stock, valued at $1,263,682.94. This represents a 64.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider directly owned 65,050 shares of the company’s stock, valued at approximately $1,647,066. The trade was a 16.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 223,368 shares of company stock worth $5,747,142. Insiders own 7.21% of the company’s stock.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC purchased a new stake in shares of Immunome during the second quarter valued at $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Immunome in the 2nd quarter worth about $576,000. Readystate Asset Management LP lifted its holdings in Immunome by 23.3% during the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock valued at $34,027,000 after buying an additional 303,958 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Immunome during the 2nd quarter valued at about $552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Immunome by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 188,636 shares of the company’s stock valued at $3,997,000 after buying an additional 1,625 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer and immune-related diseases. The company uses its antibody discovery and development capabilities to identify potentially differentiated treatments designed to address significant unmet medical needs.

Immunome’s research activities are centered on building a pipeline of monoclonal antibody programs, including candidates directed at targets relevant to oncology and inflammatory or immune-mediated conditions.